Patents by Inventor Andreas Weihofen
Andreas Weihofen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10703808Abstract: Provided are novel human ?-synuclein-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: January 9, 2018Date of Patent: July 7, 2020Assignees: Biogen International Neuroscience GmbH, University of ZürichInventors: Andreas Weihofen, Jan Grimm, Roger Nitsch, Christoph Hock
-
Patent number: 10301381Abstract: Provided are anti-human ?-synuclein-specific binding molecules, e.g., antibodies or antiben-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human ?-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human ?-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: March 7, 2018Date of Patent: May 28, 2019Assignees: Biogen International Neuroscience GmbH, University of ZürichInventors: Andreas Weihofen, Jan Grimm, Christoph Hock, Roger Nitsch, Lihe Su, Paul Weinreb
-
Publication number: 20190094245Abstract: This disclosure relates to the use of anti-?-synuclein antibody to diagnose an elevated level of ?-synuclein in the brain. Specifically, the disclosure relates to the method of assessing the levels of ?-synuclein in a blood plasma or CSF following administration to the test subject of an anti-?-synuclein antibody or antigen-binding fragment thereof, which can bind ?-synuclein with sufficient activity to alter the net efflux of ?-synuclein from brain to blood, or from brain to CSF.Type: ApplicationFiled: May 16, 2018Publication date: March 28, 2019Applicant: Biogen International Neuroscience GmbHInventors: Andreas Weihofen, Thomas Engber, Jan Grimm
-
Publication number: 20180371065Abstract: Provided are novel human ?-synuclein-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: January 9, 2018Publication date: December 27, 2018Applicants: Biogen International Neuroscience GmbH, University of ZürichInventors: Andreas Weihofen, Jan Grimm, Roger Nitsch, Christoph Hock
-
Publication number: 20180355027Abstract: Provided are anti-human ?-synuclein-specific binding molecules, e.g., antibodies or antiben-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human ?-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human ?-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: March 7, 2018Publication date: December 13, 2018Applicants: Biogen International Neuroscience GmbH, University of ZürichInventors: Andreas Weihofen, Jan Grimm, Christoph Hock, Roger Nitsch, Lihe Su, Paul Weinreb
-
Patent number: 9975947Abstract: Provided are anti-human ?-synuclein-specific binding molecules, e.g., antibodies or antiben-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human ?-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human ?-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: January 19, 2017Date of Patent: May 22, 2018Assignees: Biogen International Neuroscience GmbH, University of ZürichInventors: Andreas Weihofen, Jan Grimm, Christoph Hock, Roger Nitsch, Lihe Su, Paul Weinreb
-
Patent number: 9896504Abstract: Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: January 25, 2016Date of Patent: February 20, 2018Assignees: Biogen International Neuroscience GmbH, University of ZürichInventors: Andreas Weihofen, Jan Grimm, Roger Nitsch, Christoph Hock
-
Publication number: 20180011112Abstract: This disclosure relates to the use of anti-?-synuclein antibody to diagnose an elevated level of ?-synuclein in the brain. Specifically, the disclosure relates to the method of assessing the levels of ?-synuclein in a blood plasma or CSF following administration to the test subject of an anti-?-synuclein antibody or antigen-binding fragment thereof, which can bind ?-synuclein with sufficient activity to alter the net efflux of ?-synuclein from brain to blood, or from brain to CSF.Type: ApplicationFiled: January 19, 2017Publication date: January 11, 2018Applicant: Biogen International Neuroscience GmbHInventors: Andreas Weihofen, Thomas Engber, Jan Grimm
-
Publication number: 20170233463Abstract: Provided are anti-human ?-synuclein-specific binding molecules, e.g., antibodies or antiben-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human ?-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human ?-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: January 19, 2017Publication date: August 17, 2017Applicants: Biogen International Neuroscience GmbH, University of ZürichInventors: Andreas Weihofen, Jan Grimm, Christoph Hock, Roger Nitsch, Lihe Su, Paul Weinreb
-
Patent number: 9580493Abstract: Provided are anti-human ?-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human ?-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human ?-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: June 22, 2012Date of Patent: February 28, 2017Assignees: Biogen International Neuroscience GmbH, University of ZürichInventors: Andreas Weihofen, Jan Grimm, Christoph Hock, Roger Nitsch, Lihe Su, Paul Weinreb
-
Publication number: 20160244515Abstract: Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: January 25, 2016Publication date: August 25, 2016Applicants: Biogen International Neuroscience GmbH, University of ZurichInventors: Andreas Weihofen, Jan Grimm, Roger Nitsch, Christoph Hock
-
Publication number: 20150232542Abstract: Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: January 8, 2015Publication date: August 20, 2015Applicants: Biogen Idec International Neuroscience GmbH, University of ZurichInventors: Andreas WEIHOFEN, Jan Grimm, Roger Nitsch, Christoph Hock
-
Patent number: 8940276Abstract: Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: December 21, 2009Date of Patent: January 27, 2015Assignees: Biogen Idec International Neuroscience GmbH, University of ZurichInventors: Andreas Weihofen, Jan Grimm, Roger Nitsch, Christoph Hock
-
Publication number: 20140369940Abstract: Provided are anti-human ?-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human ?-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human ?-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: June 22, 2012Publication date: December 18, 2014Applicants: University of Zurich, Biogen IDEC International Neuroscience GmbHInventors: Andreas Weihofen, Jan Grimm, Cristoph Hock, Roger Nitsch, Lihe Su, Paul Weinreb
-
Publication number: 20140295465Abstract: This disclosure relates to the use of anti-?-synuclein antibody to diagnose an elevated level of ?-synuclein in the brain. Specifically, the disclosure relates to the method of assessing the levels of ?-synuclein in a blood plasma or CSF following administration to the test subject of an anti-?-synuclein antibody or antigen-binding fragment thereof, which can bind ?-synuclein with sufficient activity to alter the net efflux of ?-synuclein from brain to blood, or from brain to CSF.Type: ApplicationFiled: October 29, 2012Publication date: October 2, 2014Applicant: BIOGEN IDEC INTERNATIONAL NEUROSCIENCE GMBHInventors: Andreas Weihofen, Thomas Engber, Jan Grimm
-
Publication number: 20110300077Abstract: Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: December 21, 2009Publication date: December 8, 2011Applicants: University of Zurich, Panima Pharmaceuticals AGInventors: Andreas Weihofen, Jan Grimm, Roger Nitsch, Christoph Hock